Pharmaceutical Technology6d
FDA approves Roche’s Tecentriq Hybreza for cancer
The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...
rarediseaseadvisor15d
Crovalimab, Self-Administered PNH Treatment, Approved in the EU
The European Commission has approved crovalimab (PiaSky ®), a novel monoclonal antibody targeting complement protein C5, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and ...
Pharmabiz22d
European Commission approves Roche’s PiaSky for the treatment for people with paroxysmal nocturnal haemoglobinuria
Roche announced that the European Commission has approved PiaSky (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents (12 years of ...
EuropaWire22d
Tag Archives: PiaSky
(IN BRIEF) Roche has received approval from the European Commission for PiaSky® (crovalimab), a novel treatment for paroxysmal nocturnal haemoglobinuria (PNH), making it the first monthly subcutaneous ...
EuropaWire22d
Roche’s PiaSky Approved in EU as First Monthly Self-Administered Treatment for PNH
(IN BRIEF) Roche has received approval from the European Commission for PiaSky® (crovalimab), a novel treatment for paroxysmal nocturnal haemoglobinuria (PNH), making it the first monthly subcutaneous ...
Daily22d
Roche PiaSky approved in EU as monthly subcutaneous treatment for paroxysmal nocturnal haemoglobinuria
Basel: Roche has announced that the European Commission has approved PiaSky (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents (12 ...
ADVFN23d
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the ...
GlobalData on MSN23d
EC approves Roche’s monoclonal antibody PiaSky to treat PNH
The European Commission (EC) has approved Roche’s recycling monoclonal antibody, PiaSky (crovalimab), for the treatment of ...
PipelineReview.com23d
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
BASEL, Switzerland I August 27, 2024 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that ...
Yahoo Finance23d
EC approves Roche’s monoclonal antibody PiaSky to treat PNH
The European Commission (EC) has approved Roche’s recycling monoclonal antibody, PiaSky (crovalimab), for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult and adolescent ...
Morningstar23d
Roche Gets EU Approval for Blood Disorder Injection PiaSky
Roche Holding said that the European Commission has approved blood disorder injection PiaSky. The Swiss pharmaceutical giant said Tuesday that the approval follows a Phase III study which showed ...